Lexicon Pharmaceutcl (LXRX) Stock Price, Quote & News

Company Profile

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospit...

Industry: Biotechnology

Sector: Healthcare

Phone: 281 863 3000

Fax: 281 863 8088

Website: www.lexpharma.com

Address:

2445 Technology Forest Boulevard, 11th Floor, The Woodlands, United States

SniperPro Aug. 18 at 7:44 PM

$LXRX FYI, shorties 👀 — if you see BlackRock taking a position, believe me, they’ll do whatever it takes to defend their investment. 🏦💰 They don’t play around. They’re some of the most aggressive mofos you’ll ever meet in the Wall Street pit. 😈🔥 So you do you, but consider this some free advice: tread carefully. ⚠️ Shorts can get absolutely smoked when the big boys decide it’s time to move. 💀📈 Glad to be on the LONG side riding with them. 🐂🚀💎 GL, and trade smart. 🍀📈

0 · Reply

SniperPro Aug. 18 at 7:28 PM

$LXRX Yep, nice green candles despite the dark pool trying to shit all over our parade. 🟢🕯️📈 $BLK $STT $VOO $NVO 🤑💪 That said, I believe there are other big tutes quietly loading up for the next couple of weeks. 👀💰 They’re following the smart money — BlackRock, State Street, and the rest of the big boys. So who are you gonna believe? 🤔 Some broke-ass shorties screaming FUD from the sidelines… or the financial institutions that basically own Wall Street? 😂🏦 I know where I’m putting my chips. I go where the winners go. 🐂🚀 Shorts can keep fighting the tape while the institutions keep stacking. Let them get squeezed. 😈🔥 Just my 2 cents. 💎🙌📈 ...

0 · Reply

stefano62 Aug. 18 at 1:13 PM

$LXRX I think we Will float in the range 2.2-2.4 till the announcements of resubmission of zynquista, that would be the call for Q3 at beginning nov

2 · Reply

SniperPro Aug. 17 at 8:37 PM

$WETO $LXRX Out 38 from 4.75..... WOW 💥🚀💰 GL BULLS ...

4 · Reply

SniperPro Aug. 17 at 5:07 PM

$LXRX $BLK $STT $VOO $NVO Bullish Take !!! 🤑💪 Short shares available: 6.1M 👀 WTF is going on? Retail is always late to the party while the big whales 🐋 are already feasting. 🍽️💰 Either way, follow the smart money. 🧠💵 BlackRock and State Street don’t deploy millions for shits and giggles. They invest with a thesis: generate returns, build positions, and own quality companies. 📈🏦 The whales may be moving quietly, but smart money leaves footprints. 👣🐋 Stay focused. Stay patient. Stay bullish. 🚀📈🔥 ...

1 · Reply

GenericPoster Aug. 17 at 4:56 PM

$LXRX Couldn’t really find anything summarizing this weekend’s TCOYD ONE 2026 Conference (Taking Control Of Your Diabetes) held August 14–16 at Paradise Point Resort in San Diego so I asked AI (Gemini) for a summary and received this:

1 · Reply

GenericPoster Aug. 17 at 4:46 PM

$LXRX Not seeing where others have posted today’s news which reads very well for LXRX in HCM…and yet, I have not found anything ono this weekend’s diabetes conference as it related to Zynquista. Perhaps time to employ AI for the diabetes news but I still like this and perhaps should get and read the full report. Read this on HCM: https://finance.yahoo.com/healthcare/articles/hypertrophic-cardiomyopathy-market-set-transformation-143200053.html

1 · Reply

Buttermaker007 Aug. 17 at 4:29 PM

$LXRX for anybody new to this stock or investing! Your homework is to look up Eric wittouck , Raymond Debbane and Mike Exton ! Look up their relationship to lexicon pharmaceuticals! As always stay blessed everybody

1 · Reply

macrossluvsrobotech Aug. 17 at 2:30 PM

$LXRX Just in Feb Ray bought with his own money about 10 mil shares appx. Average around 1.40ish. 5 purchases of about 2 million shares. successively, consecutively. February. A money guy highly versed in Biology and the sciences.

2 · Reply

macrossluvsrobotech Aug. 17 at 2:26 PM

$LXRX Ray accumulated in the MILLIONS of shares at an average of 1.40ish... on top of the shares he already had. This February. Millions of shares. He is on the inside and knows EVERYTHING that's happening. Had a bio science degree, that allows to him to understand with perfection what's happening on the value science side. https://www.invus.com/team/raymond-debbane/

2 · Reply

Lexicon reports Q2 EPS (7c), consensus (5c)

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Lexicon Pharmaceuticals Earnings release: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Lexicon Pharmaceuticals Slides: Q2 2026

Aug 6, 2026, 8:30 AM EDT - 12 days ago

Lexicon Pharmaceuticals Quarterly report: Q2 2026

Aug 6, 2026, 8:00 AM EDT - 13 days ago

Lexicon Pharmaceuticals Registration statement: Registration filing

Aug 6, 2026, 7:30 AM EDT - 13 days ago

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

Jul 30, 2026, 8:30 AM EDT - 19 days ago

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

2026-07-27T13:15:42.000Z - 22 days ago

Lexicon completes enrollment in SONATA-HCM study

Jul 27, 2026, 8:30 AM EDT - 22 days ago

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Jun 4, 2026, 2:00 PM EDT - 2 months ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 8:00 AM EDT - 2 months ago

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

May 28, 2026, 8:30 AM EDT - 2 months ago

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

May 26, 2026, 7:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals Slides: Investor presentation

May 19, 2026, 4:30 PM EDT - 3 months ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 12, 2026, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

2026-05-11T11:01:50.000Z - 3 months ago

Lexicon price target raised to $3.10 from $2.30 at Citi

May 7, 2026, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Slides: Q1 2026

May 7, 2026, 8:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 7:30 AM EDT - 3 months ago

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

May 4, 2026, 4:05 PM EDT - 3 months ago

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

HTGC

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

2026-04-17T12:22:28.000Z - 4 months ago

Lexicon to present data at AAN annual meeting on Progress Phase 2b study

Apr 17, 2026, 8:00 AM EDT - 4 months ago

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Mar 24, 2026, 8:00 AM EDT - 5 months ago

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

2026-03-23T11:46:37.000Z - 5 months ago

Lexicon, Novo Nordisk announce initiation of LX9851 study

NVO

Mar 23, 2026, 7:30 AM EDT - 5 months ago

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 16, 2026, 8:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Mar 11, 2026, 10:00 AM EDT - 5 months ago

Lexicon Pharmaceuticals Transcript: Leerink Global Healthcare Conference 2026

2026-03-11T12:17:17.000Z - 5 months ago

Lexicon announces results from post hoc analysis on data of sotagliflozin

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes

2026-03-10T10:53:36.000Z - 5 months ago

Lexicon price target raised to $2.30 from $2.10 at Citi

2026-03-05T16:06:30.000Z - 5 months ago

Lexicon price target raised to $6 from $4 at H.C. Wainwright

Mar 5, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Annual report: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Earnings release: Q4 2025

Mar 5, 2026, 8:30 AM EST - 5 months ago

Lexicon Pharmaceuticals Slides: Q4 2025

2026-03-05T12:08:49.000Z - 5 months ago

Lexicon reports Q4 EPS (4c), consensus (7c)

Mar 5, 2026, 6:59 AM EST - 5 months ago

Lexicon Pharmaceuticals Reports Fourth Quarter 2025 Financial Results and Provides Clinical Updates

Mar 3, 2026, 4:01 PM EST - 6 months ago

Lexicon Pharmaceuticals to Participate in Three Upcoming March Investor Conferences

Feb 26, 2026, 8:30 AM EST - 6 months ago

Lexicon Pharmaceuticals to Report Fourth Quarter 2025 Financial Results on March 5, 2026

Feb 17, 2026, 7:00 AM EST - 6 months ago

Lexicon Pharmaceuticals Proxy statement: Proxy Filing

Feb 6, 2026, 5:17 PM EST - 6 months ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

Jan 30, 2026, 2:50 AM EST - 7 months ago

Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

2026-01-29T21:36:16.000Z - 7 months ago

Lexicon announces common stock offering, no amount given

Jan 29, 2026, 4:31 PM EST - 7 months ago

Lexicon Announces Proposed Public Offering of Common Stock

Jan 23, 2026, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary

2026-01-21T13:42:01.000Z - 7 months ago

Lexicon completes End-of-Phase 2 meeting with U.S. FDA for pilavapadin

Jan 21, 2026, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain

Jan 20, 2026, 6:59 AM EST - 7 months ago

Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure

VTRS

Jan 15, 2026, 3:00 PM EST - 7 months ago

Lexicon Pharmaceuticals Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 15, 2026, 3:00 PM EST - 7 months ago

Lexicon Pharmaceuticals Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-14T10:45:10.000Z - 7 months ago

Lexicon price target raised to $2.10 from $1.90 at Citi

2026-01-12T12:55:44.000Z - 7 months ago

Lexicon sees cash runway into 2027

Jan 12, 2026, 7:30 AM EST - 7 months ago

Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference

2026-01-09T13:40:14.000Z - 7 months ago

Lexicon publishes White Paper on treatments for chronic pain

Jan 9, 2026, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain”

Jan 7, 2026, 8:30 AM EST - 7 months ago

Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 10, 2025, 8:30 AM EST - 8 months ago

Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851

Dec 5, 2025, 8:30 AM EST - 9 months ago

Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum

Dec 4, 2025, 9:10 AM EST - 9 months ago

Lexicon Pharmaceuticals Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 3, 2025, 9:00 AM EST - 9 months ago

Lexicon Pharmaceuticals Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:30 AM EST - 9 months ago

Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences

Nov 18, 2025, 12:00 PM EST - 9 months ago

Lexicon Pharmaceuticals Transcript: Jefferies London Healthcare Conference 2025

Nov 14, 2025, 7:00 AM EST - 9 months ago

Lexicon Pharmaceuticals Slides: Corporate presentation

Nov 11, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference

Nov 8, 2025, 2:30 PM EST - 10 months ago

Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 8:30 AM EST - 10 months ago

Lexicon Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 7:30 AM EST - 10 months ago

Lexicon Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides R&D Updates

Nov 4, 2025, 8:30 AM EST - 10 months ago

Data Demonstrating Unique Benefits of Sotagliflozin in Diverse Patient Populations will be Presented at the Hypertrophic Cardiomyopathy Society and American Heart Association's Sessions 2025 in New Orleans

Oct 30, 2025, 8:30 AM EDT - 10 months ago

Lexicon Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 14, 2025, 8:00 AM EDT - 11 months ago

Lexicon Pharmaceuticals Presents Additional Pilavapadin Data in Diabetic Peripheral Neuropathic Pain at 19th Annual Pain Therapeutics Summit

Oct 8, 2025, 7:59 AM EDT - 11 months ago

Lexicon Pharmaceuticals Convenes Roundtable to Address Public Policy Gaps for People with Chronic Pain

Sep 22, 2025, 4:00 PM EDT - 11 months ago

Lexicon Pharmaceuticals Announces Update on Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 17, 2025, 7:00 AM EDT - 1 year ago

Pilavapadin Provides Meaningful Pain Reduction in Adults with Diabetic Peripheral Neuropathic Pain (DPNP) in Data Presented at the European Association for the Study of Diabetes (EASD) and NEUROdiab Annual Meetings

Sep 11, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings

Sep 8, 2025, 2:30 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Announces Submission of Additional Data to U.S. FDA Supporting the Benefit-Risk Profile of Zynquista® in Type 1 Diabetes

Sep 4, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present New Preclinical Data on Pilavapadin in Chemotherapy-Induced Pain and Multiple Sclerosis Pain at NeuPSIG 2025

Sep 3, 2025, 1:45 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: Citi's Biopharma Back to School Conference

Sep 3, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025

Sep 2, 2025, 8:30 AM EDT - 1 year ago

Sotagliflozin Provides Consistent Relative Risk Reduction in Heart Failure and Major Cardiovascular Events Across All Age Ranges, Including Greater Than 75, in Data Presented at the European Society of Cardiology (ESC) 2025 Congress

Aug 27, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Participate at Two Upcoming Investor Conferences

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Quarterly report: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Earnings release: Q2 2025

Aug 6, 2025, 8:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Q2 2025

Aug 6, 2025, 7:30 AM EDT - 1 year ago

Lexicon Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 23, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025

Jul 18, 2025, 8:00 AM EDT - 1 year ago

Lexicon to Present Patient-reported Data on Diabetic Peripheral Neuropathic Pain (DPNP) at the 7th Annual Meeting of the American Society of Pain and Neuroscience (ASPN 2025)

Jun 25, 2025, 7:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals Slides: Corporate Presentation

Jun 23, 2025, 8:00 AM EDT - 1 year ago

Data Demonstrating Sotagliflozin Reduces the Risk of Clinically Important Hypoglycemic Events in Adults with Type 1 Diabetes When Added to Insulin Presented at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 18, 2025, 8:30 AM EDT - 1 year ago

Lexicon to Present Data at the 85th Scientific Sessions of the American Diabetes Association (ADA)

Jun 5, 2025, 12:50 PM EDT - 1 year ago

Lexicon Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2025

May 29, 2025, 8:00 AM EDT - 1 year ago

Lexicon Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

SniperPro Aug. 18 at 7:44 PM

0 · Reply

SniperPro Aug. 18 at 7:28 PM

0 · Reply

stefano62 Aug. 18 at 1:13 PM

$LXRX I think we Will float in the range 2.2-2.4 till the announcements of resubmission of zynquista, that would be the call for Q3 at beginning nov

2 · Reply

SniperPro Aug. 17 at 8:37 PM

$WETO $LXRX Out 38 from 4.75..... WOW 💥🚀💰 GL BULLS ...

4 · Reply

SniperPro Aug. 17 at 5:07 PM

1 · Reply

GenericPoster Aug. 17 at 4:56 PM

1 · Reply

GenericPoster Aug. 17 at 4:46 PM

1 · Reply

Buttermaker007 Aug. 17 at 4:29 PM

1 · Reply

macrossluvsrobotech Aug. 17 at 2:30 PM

2 · Reply

macrossluvsrobotech Aug. 17 at 2:26 PM

2 · Reply

Cheesyisi Aug. 17 at 2:22 PM

$LXRX

0 · Reply

macrossluvsrobotech Aug. 17 at 2:21 PM

$LXRX Total 5 = only 4 pics can load at a time. Study these purchases closely.

0 · Reply

macrossluvsrobotech Aug. 17 at 2:17 PM

$LXRX This is all I care about. 5 purchases from Ray Debbane. All in Feb. See Below.

0 · Reply

macrossluvsrobotech Aug. 17 at 2:04 PM

$LXRX He's creating network.

0 · Reply

TheMotleyMonk Aug. 17 at 9:03 AM

$LXRX A potential competitor in the heart failure space? https://www.sciencedaily.com/releases/2026/08/260814235858.htm

1 · Reply

Anon_ymous1 Aug. 16 at 10:01 PM

$LXRX So i gather Zynquista and HCM are truly our main cards now. They were so quiet about Pilavapadin that i even forgot it exists.

2 · Reply

SandstoneSA Aug. 16 at 4:41 PM

$LXRX Hopefully, that with other institution increasing shares is a good sign..

1 · Reply

Jas7235355 Aug. 16 at 4:39 PM

$LXRX what does this show me?

0 · Reply

Kocatka Aug. 16 at 4:11 PM

$LXRX https://fintel.io/i13fs/artal

0 · Reply

Kocatka Aug. 16 at 4:06 PM

$LXRX Artal Continues to reduce portfolio. https://www.sec.gov/Archives/edgar/data/1053906/000119312526274180/xslF345X06/ownership.xml

2 · Reply

Jdwingy Aug. 16 at 7:31 AM

$LXRX There is one fresh institutional move worth flagging: Ishara Investments LP. Its 14 August 2026 13F shows 1,271,000 LXRX shares, up 40.91% from the prior quarter — roughly 369,000 additional shares — with a quarter-end value of about $3.05 million. This one looks active rather than index-driven. Ishara’s disclosed portfolio is heavily concentrated in biotech and pharma names such as Acadia, Xeris Biopharma, BioMarin, Praxis and Ultragenyx, and LXRX now represents about 2.24% of its reported portfolio. That makes Ishara more interesting to me than another Vanguard/BlackRock-style increase: it’s a specialist healthcare investor deliberately adding about 41% to an existing LXRX position. The holding is as of 30 June 2026; the filing itself was submitted 14 August 2026.

0 · Reply

Anon_ymous1 Aug. 15 at 3:54 PM

$LXRX How i wish i had ammo at 0.30$. But I think there is a good amount of money to be made here with Zynquista resubmission and HCM results about to be rolled out for us.

1 · Reply

Market Cap	1.04B
Revenue (ttm)	49.80M
Net Income (ttm)	-50.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-101.08%
Debt to Equity Ratio	0.29

Volume	2,904,900
Avg Vol	3,540,374
Day's Range	N/A - N/A
Shares Out	444.96M
Stochastic %K	87%
Beta	1.08
Analysts	Sell
Price Target	$3.86